We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Chitotriosidase Expression in Sarcoidosis Limited by Gene Expression

By LabMedica International staff writers
Posted on 06 Jan 2021
Print article
Image: The Applied Biosystems Veriti 96-Well Thermal Cycler (Photo courtesy of Thermo Fisher Scientific).
Image: The Applied Biosystems Veriti 96-Well Thermal Cycler (Photo courtesy of Thermo Fisher Scientific).
Sarcoidosis is a multisystem granulomatous disease which affects individuals worldwide of all ages irrespective of ethnicity or race. It is often recognized accidentally when a routine chest radiographic picture shows bilateral hilar lymphadenopathy.

Sarcoidosis patients should undergo multiple clinical examinations including invasive tissue sampling and histopathologic evaluation for definite diagnosis. Several laboratory tests have been developed including serum angiotensin-converting enzyme (ACE) activity which is one of the most frequently measured serum biomarkers having high specificity, but low sensitivity for sarcoidosis.

Clinical scientists at the University of Debrecen (Debrecen, Hungary) enrolled 80 sarcoidosis patients and the diagnosis of sarcoidosis was verified by histopathologic examination of mediastinal lymph node or lung biopsy samples. As controls 133 adults were enrolled who no signs of heart failure (normal ejection fraction). In the case of the sarcoidosis patients, blood samples were taken immediately before biopsy. Genomic DNA was prepared using NucleoSpin Blood kit (Macherey-Nagel GmbH, Düren, Germany).

Serum chitotriosidase (CTO) concentration was measured by two commercially available ELISA kits: Merck KGaA, Darmstadt, Germany and Thermo Fisher Scientific, Waltham, MA, USA. Absorbance values of wells were measured on a ClarioStar microplate reader (BMG Labtech GmbH, Ortenberg, Germany. The team also determined CTO gene duplication polymorphism, direct DNA sequencing of CTO gene and examined cis–trans configuration of CTO gene mutations. The DNA segment was amplified using a Thermo Fisher Scientific Veriti 96-well Thermal Cycler instrument. One of the most frequent polymorphism is caused by a 24-base-pair duplication in exon 10 of the CTO gene (c.1049_1072dup24; rs3831317; referred to as Dup24).

The scientists reported that CTO activities were lower in healthy individuals and sarcoidosis patients heterozygous for Dup24 mutation (472 ± 367 mU/L; 2,300 ± 2,105 mU/L) than in homozygous wild types (838 ± 856 mU/L; 5,125 ± 4,802 mU/L). Sera of Dup24 homozygous individuals had no CTO activity. CTO concentrations were also lower in healthy individuals and sarcoidosis patients heterozygous for Dup24 mutation (7.2 ± 1.9 µg/L; 63.16 ± 56.5 µg/L) than in homozygous wild types (18.9 ± 13.0 µg/L; 157.1 ± 132.4 µg/L) respectively, suggestive for an interaction between Dup24 mutation and CTO concentration determinations.

The authors concluded that the presence of frequent polymorphisms and rare mutations that diminish or abolish CTO activity may hamper the use of CTO as a diagnostic tool in sarcoidosis. These mutations have also effects on currently available CTO concentration measuring techniques, thus CTO activity measurement cannot be replaced by them. Only genotyping of the CTO gene is available to avoid misinterpreting laboratory findings today, furthermore it can assist in recognition of mutations with low allele frequencies in a given population. The study was published on December 8, 2020 in the journal Clinica Chimica Acta.

Related Links:
University of Debrecen
Macherey-Nagel
Merck KGaA
Thermo Fisher Scientific
BMG Labtech



Print article

Channels

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.